PHAR (Pharming Group) Tariff Resilience Score: 6/10 (As of Jul. 03, 2026)


PHAR Pharming Group PHAR
76 GF Score
Price $13.77
GF Value $14.36
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Tariff Resilience Score?

Pharming Group PHAR +0.84% 76 Tariff Resilience Score is 6 as of Jul. 03, 2026. GuruFocus rates PHAR with a GF Score™ of 76/100 and a GF Value™ of $14.36 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,373 Biotechnology companies, Pharming Group ranks better than 75.97% on this metric.

Pharming Group has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Pharming Group has Pharming Group's pharmaceutical products face moderate tariff exposure. The company relies on global supply chains but benefits from some industry-specific exemptions and pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pharming Group might have Average Resilient.

Pharming Group  (NAS:PHAR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pharming Group Tariff Resilience Score Related Terms

PHAR vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Pharming Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pharming Group's Tariff Resilience Score falls into.


PHAR
76GF Score
Pharming Group PHAR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Pharming Group (PHAR) has a Tariff Resilience Score of 6 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pharming Group ranks #330 out of 1373 companies in the Biotechnology industry, placing it in the top 24%.
Is Pharming Group's Tariff Resilience Score too high?
Pharming Group's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Pharming Group's value of 6 is 50% above this industry median. Based on the distribution chart, Pharming Group ranks #330 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #330 out of 1373 companies for Tariff Resilience Score. This places Pharming Group in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Pharming Group's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.36, compared to a current price of $13.77 — trading 4.1% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Pharming Group's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pharming Group (PHAR), the current Tariff Resilience Score is 6 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.77 is trading 4.1% below its estimated GF Value™ of $14.36. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Tariff Resilience Score: 6
  • GF Value™: $14.36 vs. price of $13.77 (4.1% below fair value)
  • GF Score™: 76/100 with 1 warning sign
  • Industry Position: 50% above the Biotechnology median (#330 of 1373)

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
76GF Score

Get the complete analysis for PHAR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.77
Price
$14.36
GF Value